These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19394693)

  • 1. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors.
    Nand R; Bryke C; Kroft SH; Divgi A; Bredeson C; Atallah E
    Leuk Res; 2009 Aug; 33(8):1144-6. PubMed ID: 19394693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
    Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller MC; Beneke H; Müller L; Del Valle F; Aulitzky WE; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker SJ; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross NC; Reiter A
    Leukemia; 2007 Jun; 21(6):1183-8. PubMed ID: 17377585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Congenital and childhood myeloproliferative disorders with eosinophilia responsive to imatinib.
    Abraham S; Salama M; Hancock J; Jacobsen J; Fluchel M
    Pediatr Blood Cancer; 2012 Nov; 59(5):928-9. PubMed ID: 22488677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
    Rathe M; Kristensen TK; Møller MB; Carlsen NL
    Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement.
    Tiribelli M; Barraco D; Medeot M; Marin L; Ottaviani E; De Marchi F; Damiani D; Fanin R
    Ann Hematol; 2015 Aug; 94(8):1423-4. PubMed ID: 25900790
    [No Abstract]   [Full Text] [Related]  

  • 7. A fifteen-year cytogenetic remission following interferon treatment in a patient with an indolent ETV6-ABL positive myeloproliferative syndrome.
    Mozziconacci MJ; Sainty D; Chabannon C
    Am J Hematol; 2007 Jul; 82(7):688-9. PubMed ID: 17366548
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone.
    Wang JR; Yen CC; Gau JP; Hsiao LT; Liu CY; Pai JT; Tzeng CH; Teng HW
    J Clin Pharm Ther; 2010 Dec; 35(6):733-6. PubMed ID: 21054467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement.
    Baeumler J; Szuhai K; Falkenburg JH; van Schie ML; Ottmann OG; Nijmeijer BA
    Cancer Genet Cytogenet; 2008 Aug; 185(1):37-42. PubMed ID: 18656692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib.
    Yao S; Na L; Liangding H
    Ann Hematol; 2024 Aug; 103(8):3247-3250. PubMed ID: 38888615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report.
    Pitini V; Arrigo C; Teti D; Barresi G; Righi M; Alo G
    Haematologica; 2003 May; 88(5):ECR18. PubMed ID: 12745287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glivek in the therapy of some forms of Ph- and bcr/abl-negative myeloproliferative diseases and a myeloproliferative variant of idiopathic hypereosinophilic syndrome].
    Nemchenko IS; Khoroshko ND; Turkina AG; Vinogradova OIu; Sokolova MA; Abakumov EM; Semenova EA; Zakharova AV; Domracheva EV
    Ter Arkh; 2004; 76(7):87-90. PubMed ID: 15379136
    [No Abstract]   [Full Text] [Related]  

  • 13. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders.
    Kim YK; Shin MG; Kim HR; Yang DH; Cho SH; Lee JJ; Chung IJ; Ryang DW; Kim HJ
    Leuk Res; 2008 Jun; 32(6):993-5. PubMed ID: 18055011
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).
    Walz C; Haferlach C; Hänel A; Metzgeroth G; Erben P; Gosenca D; Hochhaus A; Cross NC; Reiter A
    Genes Chromosomes Cancer; 2009 Feb; 48(2):179-83. PubMed ID: 19006078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
    Arefi M; García JL; Peñarrubia MJ; Queizán JA; Hermosín L; López-Corral L; Megido M; Giraldo P; de las Heras N; Vanegas RJ; Gutiérrez NC; Hernández-Rivas JM
    Eur J Haematol; 2012 Jul; 89(1):37-41. PubMed ID: 22587685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
    Schwaab J; Naumann N; Luebke J; Jawhar M; Somervaille TCP; Williams MS; Frewin R; Jost PJ; Lichtenegger FS; La Rosée P; Storch N; Haferlach T; Horny HP; Fabarius A; Haferlach C; Burchert A; Hofmann WK; Cross NCP; Hochhaus A; Reiter A; Metzgeroth G
    Am J Hematol; 2020 Jul; 95(7):824-833. PubMed ID: 32279331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes.
    Salaroli A; Loglisci G; Serrao A; Alimena G; Breccia M
    Ann Hematol; 2012 Nov; 91(11):1823-4. PubMed ID: 22623162
    [No Abstract]   [Full Text] [Related]  

  • 18. Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition.
    Yao J; Xu L; Aypar U; Meyerson HJ; Londono D; Gao Q; Baik J; Dietz J; Benayed R; Sigler A; Yabe M; Dogan A; Arcila ME; Roshal M; Zhang Y; Mauro MJ; Xiao W
    Haematologica; 2021 Feb; 106(2):614-618. PubMed ID: 32299902
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease.
    Curtis CE; Grand FH; Waghorn K; Sahoo TP; George J; Cross NC
    Leukemia; 2007 Aug; 21(8):1839-41. PubMed ID: 17508004
    [No Abstract]   [Full Text] [Related]  

  • 20. Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia.
    Kelly JC; Shahbazi N; Scheerle J; Jahn J; Suchen S; Christacos NC; Mowrey PN; Witt MH; Hostetter A; Meloni-Ehrig AM
    Cancer Genet Cytogenet; 2009 Jul; 192(1):36-9. PubMed ID: 19480935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.